HOME >> MEDICINE >> NEWS
Cancer immunoresistance linked to loss of tumor suppressor gene

Cancer immunoresistance may be partially due to loss of a well-known tumor suppressor gene, according to new research led by Andrew T. Parsa, MD, PhD, assistant professor of neurological surgery at the University of California, San Francisco.

The findings are reported today (December 10) online and are scheduled to appear in the January issue of Nature Medicine.

It has been known for a long time that cancer cells have many different ways to avoid the immune system, including the common strategies of hiding proteins that are normally expressed on the cell surface or making proteins that act to suppress immune responses, according to Parsa. Some researchers believe that immunoresistance may contribute to cancer progression and development, he added.

Over the past four years, Parsas lab has focused on trying to understand how specific mutations associated with high grade glioma correlate with immunoresistance. Malignant glioma is among the deadliest types of brain cancer for which there currently is no effective treatment.

My colleague James Waldron and I began screening different cell lines for mutations and trying to match these mutations up with proteins that suppress the immune system, Parsa said.

The researchers began to see an interesting trend. Glioma cells with mutation in a specific gene called the phosphatase and tensin homolog gene, or PTEN, seemed more resistant to the immune system than glioma cells with normal PTEN function. Determining the mechanism responsible for the immunoresistance proved more difficult.

Fortunately, Russ Piepers lab here at UCSF had developed a model that took normal human astrocytes and made them act like a malignant glioma. This allowed us to study the effects of PTEN mutation in a very well controlled manner, Parsa said.

In glioma patients who have lost PTEN function, the tumor cells were found to express high levels of B7-H1, a protein that c
'"/>

Contact: Carol Hyman
chyman@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
10-Dec-2006


Page: 1 2

Related medicine news :

1. American Cancer Society to hold third annual Virtual Relay For Life in Second Life
2. Cancer research summaries
3. Cancer on the agenda of the Portuguese EU Council Presidency
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Ireland Cancer Center researcher lays out benefits of aspirin to prevent colon cancer
9. Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
10. Margaret Foti receives AACR Award for Leadership and Extraordinary Achievements in Cancer Research
11. Cancer-fighting foods, supplements explored in day-long symposium, March 25

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer immunoresistance linked loss tumor suppressor gene

(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: ... Phase I trial of Lixte,s lead compound, LB‑100, is being ... John S. Kovach , M.D., the founder and ... to be completed at a single site. Accrual of patients, ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: